Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.